DelveInsight’s ‘Cytomegalovirus Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Cytomegalovirus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cytomegalovirus pipeline domain.
Key Takeaways from the Cytomegalovirus Pipeline Report
Cytomegalovirus Overview
Cytomegalovirus (CMV) is a wide-spread virus, with manifestations ranging from asymptomatic to severe end-organ dysfunction in immunocompromised patients with congenital CMV disease. Human cytomegalovirus is a member of the viral family known as herpesviruses, Herpesviridae, or human herpesvirus-5 (HHV-5). Human cytomegalovirus infections commonly are associated with the salivary glands. CMV infection may be asymptomatic in healthy people, but they can be life-threatening in an immunocompromised patient.
Cytomegalovirus Pipeline Analysis: Drug Profile
mRNA-1647: Moderna
mRNA-1647 includes six mRNAs encoding two antigens in one vaccine and is developed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex, and one mRNA encodes the glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is vital for CMV entry into most cells, including epithelial cells, while gB is essential for entry into all susceptible cells, including fibroblasts. A vaccine that develops an immune response against both pentamer and gB can prohibit CMV entry into a range of target cell types and thus inhibit primary and congenital infections.
Discover more about the emerging Cytomegalovirus drugs @ Cytomegalovirus Treatment Drugs
Cytomegalovirus Key Companies
Cytomegalovirus Pipeline Therapies
Cytomegalovirus Pipeline Therapeutics Assessment
Scope of the Cytomegalovirus Pipeline Report
Find out more about the Cytomegalovirus treatment options in development @ Cytomegalovirus Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Request for a sample report to know more about the leading companies in the cytomegalovirus pipeline segment.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/